Literature DB >> 2049739

Multi-parameter flow cytometric quantitation of the expression of the tumor-associated antigen SM3 in normal and neoplastic ovarian tissues. A comparison with HMFG1 and HMFG2.

P A van Dam1, D G Lowe, J V Watson, T W Jobling, T Chard, J H Shepherd.   

Abstract

SM3 is a monoclonal antibody that reacts with a peptide epitope in the core protein of polymorphic epithelial mucin. Multi-parameter flow cytometry was used to characterize the expression of SM3 and compare it with two related tumor-associated antigens, HMFG1 and HMFG2, in cell suspensions of 44 malignant ovarian tumors, 15 benign ovarian tumors, and 16 normal ovaries. Tumor-associated antigen expression was significantly higher in malignant ovarian neoplasms than in benign neoplasms (P less than 0.001 for all three antigens). SM3 was expressed more specifically in malignant than benign tumors but had a lower affinity than HMFG1 and HMFG2. Multi-parameter flow cytometric evaluation of a panel of monoclonal antibodies can be used to help in choosing the best antibody for immunohistochemistry, imaging, and eventually treatment of ovarian tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2049739     DOI: 10.1002/1097-0142(19910701)68:1<169::aid-cncr2820680130>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Peroperative radioimmunodetection of ovarian carcinoma using a hand-held gamma detection probe.

Authors:  T E Ind; M Granowska; K E Britton; G Morris; D G Lowe; C N Hudson; J H Shepherd
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

2.  CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.

Authors:  Pradip Bajgain; Supannikar Tawinwung; Lindsey D'Elia; Sujita Sukumaran; Norihiro Watanabe; Valentina Hoyos; Premal Lulla; Malcolm K Brenner; Ann M Leen; Juan F Vera
Journal:  J Immunother Cancer       Date:  2018-05-10       Impact factor: 13.751

Review 3.  The expansion of targetable biomarkers for CAR T cell therapy.

Authors:  Michelle H Townsend; Gajendra Shrestha; Richard A Robison; Kim L O'Neill
Journal:  J Exp Clin Cancer Res       Date:  2018-07-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.